Vaxxel acquires Transgene's DuckCelt-T17 cell line to develop vaccinesChristian Fernsby ▼ | May 4, 2020
Vaxxel SAS, a French start-up, developing vaccines against respiratory viral infections, announces the acquisition of Transgene’s proprietary DuckCelt®-T17 cell line.
Topics: Vaxxel Transgene
Through this agreement, Transgene becomes a shareholder of Vaxxel.
DuckCelt-T17, initially developed and patented by Transgene, is an avian cell line grown in suspension.
It is permissive to a variety of viruses, including Influenza viruses and human Metapneumoviruses.
The cell line has a demonstrated capability to be used at industrial scale. ■